Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor R406 after ocular delivery for retinoblastoma

Pharmaceutical Research

Volumn 31, Issue 11, 2014, Pages 3060-3072

  Pritchard, Eleanor M ^a   Stewart, Elizabeth ^a   Zhu, Fangyi ^a   Bradley, Cori ^a   Griffiths, Lyra ^a   Yang, Lei ^a   Suryadevara, Praveen Kumar ^a   Zhang, Jiakun ^a   Freeman, Burgess B ^a   Guy, R Kiplin ^a   Dyer, Michael A ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Ocular drug delivery; R406; Retinoblastoma; Spleen tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; N4-(2,2-DIMETHYL-3-OXO-4H-PYRID(1,4)OXAZIN-6-YL)-5-FLUORO-N2-(3,4,5-TRIMETHOXYPHENYL)-2,4-PYRIMIDINEDIAMINE; OXAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; SIGNAL PEPTIDE;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL DEATH; DISEASE MODEL; DRUG EFFECTS; EYE; FEMALE; HUMAN; MOUSE; RETINAL NEOPLASMS; RETINOBLASTOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; DISEASE MODELS, ANIMAL; EYE; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; OXAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 84932085919     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1399-y     Document Type: Article

References (40)

1. Federico S, Brennan R, Dyer MA. Childhood cancer a developmental biology: a crucial partnership. Curr Top Dev Biol. 2011;94:1-13.
2. Shields CL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control. 2004;11(5):317-27.
3. Eng C, Li FP, Abramson DH, Ellsworth RM, Wong RL, Goldman MB, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85(14):1121-8.
4. Nahum MP, Gdal-On M, Kuten A, Herzl G, Horovitz Y, Arush MWB. Long-term follow-up of children with retinoblastoma. Pediatric Hematol Oncol. 2001;18(3):173-9.
5. Hijiya N, Ness KK, Ribeiro RC, Hudson MM. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer. 2009;115(1):23-35.
6. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481(7381):329-34.
7. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319(3):998-1008.
8. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363(14):1303-12.
9. Sweeny DJ, Li W, Clough J, Bhamidipati S, Singh R, Park G, et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos. 2010;38(7):1166-76.
10. Nemeth KM, Federico S, Carcaboso AM, Shen Y, Schaiquevich P, Zhang J, et al. Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer. 2011;117(2):421-34.
11. Brennan RC, Federico S, Bradley C, Zhang J, Flores-Otero J, Wilson M, et al. Targeting the p53 pathway in retinoblastoma with subconjunctival nutlin-3a. Cancer Res. 2011;71(12):4205-13.
12. Yuan H, Li N, Lai Y. Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs. Drug Metab Dispos. 2009;37(7):1443-7.
13. Cardillo JA, Melo Jr LA, Costa RA, Skaf M, Belfort Jr R, Souza-Filho AA, et al. Comparison of intravitreal versus posterior sub-Tenon'scapsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112(9):1557-63.
14. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109(9):1709-16.
15. Institute of Laboratory Animal Resources. Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. Washington: National Academy Press; 1996.
16. Järvinen T, Järvinen K. Prodrugs for improved ocular drug delivery. Adv Drug Deliv Rev. 1996;19(2):203-24.
17. Weijtens O, Feron EJ, Schoemaker RC, Choen AF, Lentjes EGWM, Romijn FPHTM, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999;128(2):192-7.
18. Weijtens O, Schoemaker RC, Lentjes EGWM, Romijn FPHTM, Cohen AF, van Meurs JC. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology. 2000;107(10):1932-8.
19. Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078-83.
20. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeing from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268-71.
21. Shields CL, Fulco EM, Arias JD, Alarcon C, Pellegrini M, Rishi P, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye. 2013;27(2):253-64.
22. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv. 2007;4(4):371-88.
23. Campbell M, Ozaki E, Humphries P. Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach. Expert Opin Drug Deliv. 2010;7(7):859-69.
24. Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov. 2012;11(7):541-59.
25. Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol. 2008;36(1):49-62.
26. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41(5):961-4.
27. Carcaboso AM, Bramuglia GF, Chantada GL, Fandiño AC, Chiappetta DA, de Davila MTG, et al. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci. 2007;48(8):3761-7.
28. Murray TG, Cicciarelli N, O'Brien JM, Hernández E, Mueller RL, Smith BJ, et al. Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Arch Ophthalmol. 1997;115(10):1286-90.
29. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106(10):1947-50.
30. Hayden BC, Jockovich M-E, Murray TG, Voigt M, Milne P, Kralinger M, et al. Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci. 2004;45(10):3644-9.
31. Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, et al. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos. 2011;39(1):15-21.
32. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl. 2009;195:S13-9.
33. Di Lorenzo R, Brogli A. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat. 2010;6:573-81.
34. Singh R, Masuda ES, Payan DG. Discovery and development of spleen tyrosine kinase (SYK) inhibitors. J Med Chem. 2012;55(8):3614-43.
35. D'Cruz OJ, Uckun FM. Targeting spleen tyrosine kinase (SYK) for treatment of human disease. J Pharm Drug Deliv Res 201;1:2.
36. Ruzza P, Biondi B, Calderan A. Therapeutic prospect of Syk inhibitors. Expert Opin Ther Patents. 2009;19(10):1361-76.
37. Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013;344(2):378-87.
38. Reilly MP, Sinha U, André P, Taylor SM, Pak Y, DeGuzman FR, et al. PRT-060318, a novel Syk inhibitor, prevents heparin induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. 2011;117(7):2241-6.
39. Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S, et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia. 2009;23(4):686-97.
40. Juin P, Geneste O, Gautier F, Depil SJ, Campone M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer. 2013;13(7):455-65.